- Groundbreaking results published in leading peer-reviewed scientific journal
- Important academic validation of underlying science behind Cognetivity’s cognitive assessment platform
VANCOUVER, Jan. 31, 2019 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN; FWB: 1UB; OTCQB: CGNSF) today announced that results from its research and development program into its Integrated Cognitive Assessment (ICA) platform have been published in a leading peer-reviewed academic journal, Scientific Reports, from the publishers of Nature.
The paper describes results from key studies validating the effectiveness of the ICA’s unique approach of using a rapid visual categorization task for detecting changes in cognitive performance and its potential for use in early detection of mental disorders, including dementia, and micro-monitoring of cognitive performance.
Cognetivity’s CEO and Director, Dr. Sina Habibi, commented: “We are delighted to announce this first peer-reviewed publication of our groundbreaking research in the area of cognitive performance measuring. Now that we have been granted patents covering key areas of our technology, we have been able to release details of our research and development program and some of the excellent results which validate our approach for our sensitive, repeatable and fully scalable solution to the early detection of conditions that involve cognitive impairment. It is our aim to make our technology available to help as many people as possible, whether through its use in clinical environments for the crucial early detection of conditions such as dementia, or through allowing people to measure their ongoing cognitive performance in a meaningful way as part of their overall health monitoring activities.”
About Cognetivity Neurosciences Ltd.
Cognetivity is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA) for use in medical and commercial environments. Cognetivity’s ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain, potentially allowing early diagnosis of dementia. Cognetivity aims to develop the ICA through planned clinical studies to the market in North America and Europe.
For more information please visit – www.cognetivity.com
About Scientific Reports
Scientific Reports is an online, open access journal from the publishers of Nature. The journal publishes scientifically valid primary research from all areas of the natural and clinical sciences. https://www.nature.com/content/scirep-facts/index.html
ON BEHALF OF THE BOARD
Chief Executive Officer and Director
FORWARD LOOKING STATEMENTS:
The forward-looking information contained in this press release is made as of the date of this press release and, except as required by applicable law, the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as may be required by law. By its very nature, such forward-looking information requires the Company to make assumptions that may not materialize or that may not be accurate. This forward-looking information is subject to known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such information.
The Exchange does not accept responsibility for the adequacy or accuracy of this release
SOURCE Cognetivity Neurosciences Ltd
View original content: http://www.newswire.ca/en/releases/archive/January2019/31/c2640.html